The January 2024 guidelines update also changed mirvetuximab soravtansine plus bevacizumab from a category 2B recommendation to a category 2A recommendation for platinum-resistant, FRα-expressing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results